Home
Life Sciences

Sector: Life Sciences

Huawei, Intel among big firms selling patents in June-recorded transactions

Two deals could bring NPE risk but others stem from bankruptcies, buying and selling of business units and company product collaborations

Historic moment as UPC hands down two full decisions within 24 hours of each other

The Unified Patent Court has handed patentees a win and a loss in its first on-the-merits rulings

Pharma patent litigation highlights in Southeast Asia in early 2020s

Rouse highlights some of the most important pharma patent decisions issued by Southeast Asian courts in the past four years

Latest content

Buying time, quality over quantity, the gathering litigation storm and more from IPBC China 2015

There were over 250 attendees at a packed-to-the-rafters IPBC China, which took place this week at the Shangri-La Hotel in Haidian, Beijing. Delegates, mostly local IP professionals working inside major Chinese businesses, participated in a series…

23 April 2015

Don't be surprised if big technology companies are next to feel the PTAB heat from investors

Given the important role that it now plays in so much US patent litigation, it is easy to forget that the Patent Trial and Appeal Board is not yet three years old. Established in September 2012 under a provision of the America Invents Act, the PTAB…

20 April 2015

A match made in heaven – IPNav founder and high-tech unite to save current PTAB claim standard?

If there is one area of patent reform where most US legislators seem able to agree, it’s that the Patent Trial and Appeal Board’s (PTAB) use of the broadest reasonable claim interpretation standard in interpreting patent claims should be abandoned…

16 April 2015

If pharma has high-quality patents IPRs should not be an issue, says hedge fund investor

Perhaps the patent story of the year so far has been the inter partes reviews (IPR) launched at the Patent Trial and Appeal Board (PTAB) against a series of pharmaceutical patents by hedge fund investors. Kyle Bass, founder of Hayman Capital…

09 April 2015

Bass/Spangenberg file new pharma IPR re-exams

Hedge fund investor Kyle Bass and former IPNav CEO Erich Spangenberg have filed inter partes reviews against patents owned by Shire Pharmaceuticals and NPS Pharmaceuticals. The Irish headquartered Shire recently bought NPS in a $5.2bn deal. Its…

02 April 2015

Eli Lilly deal shows there is high-quality IP in China for foreign businesses that are prepared to search it out

Suzhou-based biopharmaceuticals firm Innovent Biologics has entered into an alliance with Eli Lilly & Co which will see its cancer therapies developed and marketed worldwide by the US company in a deal potentially worth upwards of $456 million.…

02 April 2015

New data confirms that US patents are being knocked out on 101 grounds in record numbers

Lex Machina’s second annual review of the patent litigation landscape in the US is out today and the IAM blog has had an exclusive preview of what is a very comprehensive piece of work.The main headline figure for last year – that the number of…

26 March 2015

The biggest impact on patent quality would be the USPTO injecting certainty into the eligibility debate

Next week the USPTO will hold its first summit on patent quality. Having both appointed its first deputy commissioner on the issue and announced its enhanced patent quality initiative earlier this year, it’s easy to see what the agency currently…

20 March 2015

As patent reform battle lines are drawn in the Senate it’s looking like a long haul

In the House of Representatives, at least, patent reform 2.0 has so far followed the expected legislative arc. Congressman Goodlatte reintroduced the Innovation Act in February and, barring a miraculous shift in support, the only serious question…

19 March 2015

Another investor attack launched against a pharma patent at the PTAB; and Kyle Bass is not involved

An IPR has been filed against an Allergan patent by an investment firm in a move that will heighten fears in the life sciences industries about the potential damage the PTAB process could do to their IP rights. The latest move comes after two…

17 March 2015

Unlock unlimited access to all IAM content